Safety and efficacy of high-dose tamoxifen and sulindac for desmoid tumor in children: Results of a Children's Oncology Group (COG) Phase II Study

Authors

Stephen X. Skapek, University of Texas Southwestern Medical Center
James R. Anderson, University of NebraskaFollow
D. Ashley Hill, George Washington UniversityFollow
David Henry, University of Kansas
Sheri L. Spunt, University of Tennessee
William Meyer, University of Oklahoma
Simon Kao, University of Iowa
Fredric A. Hoffer, University of Washington
Holcombe E. Grier, Dana-Farber Cancer Institute and Children's Hospital, Boston, MA
Douglas S. Hawkins, University of Washington
R. Beverly Raney, UT MD Anderson Cancer Center, Houston, TX

Document Type

Journal Article

Publication Date

7-2013

Journal

Pediatric Blood and Cancer

Volume

Volume 60, Issue 7

Inclusive Pages

1108-1112

Comments

This is an open access PubMed Central article. Click on link for full-text access.

APA Citation

Skapek, S. X., Anderson, J. R., Hill, D. A., Henry, D., Spunt, S. L., Meyer, W., Kao, S., Hoffer, F.A., Grier, H.E., Hawkins, D.S., Raney, R. B. (2013). Safety and efficacy of high-dose tamoxifen and sulindac for desmoid tumor in children: Results of a children's oncology group (COG) phase II study. Pediatric Blood and Cancer, 60(7), 1108-1112.

Peer Reviewed

1

Open Access

1